Nimenrix®, Menactra® or Menveo® Vaccines for Meningococcal (Groups A, C, Y and W-135) Polysaccharide
Nimenrix®/Menactra®/Menveo® are vaccines that protect against meningococcal disease.
- It can be given to people from 2 to 55 years of age for prevention of invasive meningococcal disease caused by N. meningitides serogroups A, C, Y, and W-135.
- In Ontario, Nimenrix®, Menactra® or Menveo® are routinely given to Grade 7 students.
- It can also be given to travelers and those at high risk of getting meningococcal disease.
- Nimenrix®,Menactra® or Menveo® are a 0.5 ml injection given in the deltoid muscle (shoulder).
Mild side effects may occur, such as:
- Redness and tenderness at the injection site.
- Headache, fatigue, aches and pains, fever, chills, decreased appetite, vomiting and rash.
Severe side effects are rare.
Abnormal reactions to see a doctor for and report to the Health Unit:
- Hives;
- Swelling of the face or mouth;
- High fever (over 40ºC or 104ºF);
- Very pale colour and serious drowsiness;
- Convulsions or seizures;
- Other serious problems.
Allergic reactions such as hives, wheezing, swelling of the face and mouth, difficulty breathing, convulsions or seizures are extremely rare. However, if these symptoms occur, seek medical attention immediately, and contact the North Bay Parry Sound District Health Unit, Vaccine Preventable Diseases Program at (705) 474-1400 ext. 5252 direct fax: (705) 474-9399 to report the abnormal reaction once care has been received.
Invasive Meningococcal Disease
Meningitis is an infection of the fluid that surrounds the brain and the spinal cord. Invasive meningococcal disease also causes infections in the blood. These infections can be serious and can even cause death, especially in people who have impaired immune systems, older adults, and children younger than two years of age.
Symptoms include a stiff neck, high fever, headaches, and sensitivity to light, nausea, and vomiting. Severe symptoms can include a rash, low blood pressure, blood clotting, multi-organ failure, and coma.